PURPOSE: To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when administered in combination to patients with advanced solid tumor malignancies. EXPERIMENT DESIGN: Subjects received 10 mg of panobinostat three times weekly, 5 or 10 mg everolimus daily, and bevacizumab at 10 mg/kg every 2 weeks. Dose-limiting toxicities (DLTs) were assessed in cycle 1; toxicity evaluation was closely monitored throughout treatment. Treatment continued until disease progression or undesirable toxicity. Protein acetylation was assessed in peripheral blood mononuclear cells (PBMC) both at baseline and on treatment. RESULTS: Twelve subjects were evaluable for toxicity and nine subjects for response. DLTs in cohort 1 included grade 2 esophagitis and grade 3 oral mucositis; DLTs in cohort -1 were grade 2 ventricular arrhythmia and grade 2 intolerable skin rash. Common adverse events were diarrhea (50 %), headache (33 %), mucositis/stomatitis (25 %), hyperlipidemia (25 %), and thrombocytopenia (25 %). There was 1 partial response; an additional 2 subjects had stable disease as best response. No consistent changes in protein acetylation in PBMC were observed in samples available from eight patients on treatment compared with baseline. CONCLUSIONS: Bevacizumab, everolimus, and panobinostat in combination at the lowest proposed doses did not have an acceptable safety and tolerability profile and did not consistently inhibit HDAC activity; therefore, we do not recommend further evaluation.
PURPOSE: To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when administered in combination to patients with advanced solid tumor malignancies. EXPERIMENT DESIGN: Subjects received 10 mg of panobinostat three times weekly, 5 or 10 mg everolimus daily, and bevacizumab at 10 mg/kg every 2 weeks. Dose-limiting toxicities (DLTs) were assessed in cycle 1; toxicity evaluation was closely monitored throughout treatment. Treatment continued until disease progression or undesirable toxicity. Protein acetylation was assessed in peripheral blood mononuclear cells (PBMC) both at baseline and on treatment. RESULTS: Twelve subjects were evaluable for toxicity and nine subjects for response. DLTs in cohort 1 included grade 2 esophagitis and grade 3 oral mucositis; DLTs in cohort -1 were grade 2 ventricular arrhythmia and grade 2 intolerable skin rash. Common adverse events were diarrhea (50 %), headache (33 %), mucositis/stomatitis (25 %), hyperlipidemia (25 %), and thrombocytopenia (25 %). There was 1 partial response; an additional 2 subjects had stable disease as best response. No consistent changes in protein acetylation in PBMC were observed in samples available from eight patients on treatment compared with baseline. CONCLUSIONS:Bevacizumab, everolimus, and panobinostat in combination at the lowest proposed doses did not have an acceptable safety and tolerability profile and did not consistently inhibit HDAC activity; therefore, we do not recommend further evaluation.
Authors: David Z Qian; Yukihiko Kato; Shabana Shabbeer; Yongfeng Wei; Hendrik M W Verheul; Brenda Salumbides; Tolib Sanni; Peter Atadja; Roberto Pili Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Balveen Kaur; Fatima W Khwaja; Eric A Severson; Shannon L Matheny; Daniel J Brat; Erwin G Van Meir Journal: Neuro Oncol Date: 2005-04 Impact factor: 12.300
Authors: Fatima Rangwala; Johanna C Bendell; Mark F Kozloff; Christy C Arrowood; Andrew Dellinger; Jennifer Meadows; Sandra Tourt-Uhlig; Jennifer Murphy; Kellen L Meadows; Aijing Starr; Samuel Broderick; John C Brady; Stephanie M Cushman; Michael A Morse; Hope E Uronis; S David Hsu; S Yousuf Zafar; James Wallace; Alexander N Starodub; John H Strickler; Herbert Pang; Andrew B Nixon; Herbert I Hurwitz Journal: Invest New Drugs Date: 2014-04-09 Impact factor: 3.850
Authors: T Mitamura; S Pradeep; M McGuire; S Y Wu; S Ma; H Hatakeyama; Y A Lyons; T Hisamatsu; K Noh; A Villar-Prados; X Chen; C Ivan; C Rodriguez-Aguayo; W Hu; G Lopez-Berestein; R L Coleman; A K Sood Journal: Oncogene Date: 2017-10-23 Impact factor: 9.867
Authors: Eva Juengel; Jasmina Makarević; Igor Tsaur; Georg Bartsch; Karen Nelson; Axel Haferkamp; Roman A Blaheta Journal: PLoS One Date: 2013-01-23 Impact factor: 3.240